Intelligent Bio Solutions Inc. (NASDAQ: INBS), a leader in non-invasive medical testing technologies, is set to present its pharmacokinetic study at the ADLM 2025 Clinical Lab Expo in Chicago. The study underscores the efficacy of the company's Intelligent Fingerprinting Drug Screening System, demonstrating that fingerprint sweat can accurately reflect codeine levels comparable to those found in blood and saliva. This advancement supports the system's role as a non-invasive, rapid, and dignified solution for drug screening in various settings, including workplaces, clinical environments, and justice systems.
Daniel Brown, Head of Clinical Affairs at INBS, will present the findings during the Poster Hall sessions at the expo. The company's innovative approach to drug screening, which utilizes fingerprint sweat analysis, offers a hygienic and cost-effective alternative to traditional methods. With results available in under ten minutes and sample collection taking mere seconds, the system is particularly suited for safety-critical industries. INBS's technology is already making an impact globally, with over 450 accounts across 24 countries, serving sectors such as construction, manufacturing, transport, and drug treatment organizations.
The presentation at the ADLM 2025 Clinical Lab Expo marks a significant milestone for INBS, as it continues to expand the applications of its fingerprint sweat analysis technology. The study's findings not only validate the system's accuracy but also open the door for its use in broader fields beyond drug screening. For more details on the study and INBS's innovative solutions, visit https://ibn.fm/suGlJ.
The implications of this announcement are substantial for public health and workplace safety. By providing a non-invasive method that matches the accuracy of blood and saliva tests, the system addresses privacy concerns and reduces the discomfort associated with traditional drug screening. This is particularly important in justice systems and clinical settings where dignity and efficiency are paramount. The rapid turnaround time—under ten minutes for results—makes it feasible for real-time screening in safety-critical industries like transportation and manufacturing, potentially preventing accidents and enhancing compliance.
Furthermore, the global adoption of INBS's technology, with over 450 accounts in 24 countries, indicates a growing acceptance and trust in fingerprint-based testing. This could drive regulatory changes and industry standards, encouraging wider implementation. The study's validation of codeine detection suggests potential for monitoring other substances, expanding into areas like medication adherence or toxicology. As the company presents at a major expo like ADLM 2025, it gains visibility among healthcare professionals, potentially accelerating partnerships and further innovation in non-invasive diagnostics.
